Skip to content Skip to footer
Subscribe Now
Top Performing Drug of 2021 – Eylea (September Edition)
INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…
September 22, 2022

Read more

Spotlight Interview_Rohan (Ro) F. Hastie
CXO TALKS

Spotlight Interview with Rohan (Ro) F. Hastie, President & CEO at Metabolon

PharmaShots had its third interview for the “Spotlight- Company of the Month- Metabolon’’. The interview was with Rohan (Ro) F. Hastie, President & CEO at Metabolon where he shared insights from the journey, products, solutions, technologies, and upcoming plans of Metabolon. Metabolon develops analytical methods and software for biomarker discovery by using metabolomics. The company…
September 22, 2022

Read more

Viewpoints_Karl Bradshaw
VIEWPOINTS

Karl Bradshaw, VP of Corporate Development at Metabolon, Shares Insights on the Partnership with The University of Oxford Parkinson’s Disease Centre

Shots: Karl spoke on Metabolon’s partnership with the University of Oxford Parkinson’s Disease Centre (OPDC) to identify new metabolomic biomarkers for the advancement of Parkinson’s research  Karl also talked about the metabolomic changes which occur in Parkinson’s disease and how Metabolon will support OPDC's mission to improve research and understanding of the biology of early…
September 21, 2022

Read more

Viewpoints_Dr. Changjin Wang
VIEWPOINTS

Dr. Changjin Wang, CEO at Frontier Biotechnologies, Shares Insights on P-I Results of its Coronavirus Mpro Inhibitor

Shots: Changjin spoke about the P-I results of their lead candidate, Bofutrelvir to treat acute and long covid. The data was presented at the poster session of the 11th International Conference on ICEID, 2022 Changjin also talked about the upcoming formulations of this innovative medicine and the initiation of its BRIGHT study covering the P-II/III…
September 19, 2022

Read more

Viewpoints_Tania Small
VIEWPOINTS

Tania Small, VP, Global Medical Oncology Head, GSK, Shares Insights on Target the Future Think Tank Challenge

Shots: Tania spoke about the Target the Future Think Tank Challenge and how it will advance and address key needs in the multiple myeloma  She also talked about GSK’s collaboration with the HealthTree Foundation to provide access, education, and support for underserved communities of multiple myeloma The interview gives a profound understanding of how GSK…
September 14, 2022

Read more

ThoughtSpot_Senior Editor
THOUGHTSPOT

ILAP and its nuance vs PRIME since BREXIT

Introduction PRIME (PRIority MEdicines) EMA launched PRIME on March 07, 2016, to support the development of medicines targeting unmet medical needs. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients faster. PRIME builds on the…
September 13, 2022

Read more

Viewpoints_Matt Killeen
VIEWPOINTS

Matt Killeen, CSO at Renovacor Shares Insights on Pipeline Expansion through its AAV Gene Therapy Program

Shots: Matt spoke about the new research program for multiple genetic segments of arrhythmogenic cardiomyopathy He also highlighted Renovacor’s research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) The interview shows Renovacor’s pipeline expansion to develop transformative therapies in genetically-driven cardiovascular diseases Smriti: Please give readers a brief insight…
September 12, 2022

Read more

Viewpoints_Carsten Linnemann
VIEWPOINTS

Carsten Linnemann, CEO at Neogene Therapeutics Shares Insights on the Approval of CTA for the P-I Trial of its TCR Therapy to Treat Solid Tumors

Carsten spoke about the approval of CTA by the Dutch regulatory authority for a P-I study evaluating its TCR therapy for the treatment of solid tumors Carsten also emphasized how NT-125 will be different from other TCR therapies The interview shows the advancement of Neogene’s pipeline developing transformative TCR therapies targeting neoantigens in solid cancers…
September 7, 2022

Read more

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer
VIEWPOINTS

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer

Shots: John spoke about the results from the P-II MOUNTAINEER Trial evaluating its lead candidate in mCRPC He also talked about TUKYSA (tucatinib) in combination with trastuzumab as a potential treatment for mCRPC The interview gives a deeper understanding of Seagen’s vision of developing transformative cancer treatment options Smriti: Share the details (ROA, MOA & formulations)…
September 6, 2022

Read more

Load more